Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report)‘s stock had its “outperform” rating reaffirmed by research analysts at Wedbush in a research report issued on Wednesday, Benzinga reports. They presently have a $15.00 target price on the biotechnology company’s stock. Wedbush’s target price indicates a potential upside of 339.88% from the stock’s previous close. A number […]

Veralto (NYSE:VLTO – Get Free Report)‘s stock had its “outperform” rating reissued by research analysts at Wolfe Research in a note issued to investors on Tuesday, Benzinga reports. They currently have a $125.00 price objective on the stock. Wolfe Research’s price target suggests a potential upside of 29.84% from the stock’s previous close. Several other […]

Wedbush restated their outperform rating on shares of Immunic (NASDAQ:IMUX – Free Report) in a research report released on Thursday,Benzinga reports. The brokerage currently has a $45.00 price objective on the stock. Other analysts have also recently issued research reports about the company. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price target […]

Wedbush reissued their outperform rating on shares of BridgeBio Oncology Therapeutics (NASDAQ:BBOT – Free Report) in a research note released on Wednesday,Benzinga reports. The firm currently has a $25.00 price objective on the stock. A number of other research analysts have also commented on the stock. Wall Street Zen upgraded shares of BridgeBio Oncology Therapeutics […]

Disc Medicine (NASDAQ:IRON – Get Free Report)‘s stock had its “outperform” rating reiterated by research analysts at Wedbush in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $100.00 price target on the stock. Wedbush’s price target would suggest a potential upside of 30.70% from the company’s previous […]